Investigating the effect of standard treatment of classical medicine and embedding in controlling dysmenorrhea and dyspareunia caused by endometriosis in wome

Phase 3

Recruiting

Conditions: dysmenorrhea and dyspareunia caused by endometriosis.
Endometriosis, unspecified
N80.9

Registration Number: IRCT20121228011912N5

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 50

Inclusion Criteria

Diagnosis of clinical endometriosis by observing pain and tenderness in the pelvic examination along with endometriosis nodules in the vaginal examination, firm and motionless uterus and confirmed by ultrasound or MRI (observation of endometriosis cysts and nodules)
Diagnosis of grade I-IV endometriosis based on r-ASRM criteria during diagnostic laparoscopy during the previous 12 months
Dysmenorrhea complaint with EAPP score >30 or >40
normal pap smear
Age 18-45 years
Informed written consent to participate in the study

Exclusion Criteria

Unwillingness to continue the research
Non-adherence to the provided treatment regimen and incorrect or incomplete use of medication
Occurrence of any complications attributed to drug use (especially allergies)
Endometriosis who were treated with GNRH agonist less than 6 months ago, or danazol or progesterone pills less than 3 months ago, or birth control pills less than one month ago
Breastfeeding, pregnancy. Cancers of the uterus, ovaries, cervix and high-grade intraepithelial lesions

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dysmenorrhea and dyspareunia. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months later. Method of measurement: It will be evaluated using the EAPP checklist scale.;Anti-Müllerian hormone serum level and antral follicle count. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months later. Method of measurement: Measurement of anti-Müllerian hormone serum level and antral follicle count by ultrasound.

Secondary Outcome Measures

Name	Time	Method
Quality of Life. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months later. Method of measurement: Short form of World Health Organization quality of life questionnaire.